The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors.

[1]  Po-Hsuan Cameron Chen,et al.  Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge , 2022, Nature Medicine.

[2]  E. Antonarakis,et al.  Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. , 2021, European journal of cancer.

[3]  A. D'Amico,et al.  NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  L. Kiemeney,et al.  European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. , 2021, European urology.

[5]  Carrie J. Cai,et al.  Evaluation of the Use of Combined Artificial Intelligence and Pathologist Assessment to Review and Grade Prostate Biopsies , 2020, JAMA network open.

[6]  J. McKenney,et al.  Similarities and Differences in the 2019 ISUP and GUPS Recommendations on Prostate Cancer Grading: A Guide for Practicing Pathologists. , 2020, Advances in anatomic pathology.

[7]  J. Epstein,et al.  Clear Cell Adenocarcinoma in Men , 2020, The American journal of surgical pathology.

[8]  M. D. den Bakker,et al.  Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome , 2020, Virchows Archiv.

[9]  J. Eshleman,et al.  PIN‐like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations , 2020, Histopathology.

[10]  Po-Hsuan Cameron Chen,et al.  Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens , 2020, JAMA oncology.

[11]  M. Varma,et al.  Head to head: should the intraductal component of invasive prostate cancer be graded? , 2020, Histopathology.

[12]  N. Palanisamy,et al.  Gene fusion characterisation of rare aggressive prostate cancer variants—adenosquamous carcinoma, pleomorphic giant‐cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases , 2020, Histopathology.

[13]  Ximing J. Yang,et al.  The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. , 2020, Archives of pathology & laboratory medicine.

[14]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.

[15]  T. H. van der Kwast,et al.  Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens , 2020, Histopathology.

[16]  Anne E. Calvaresi,et al.  Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Litjens,et al.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma , 2020, The American journal of surgical pathology.

[18]  C. D. Savci-Heijink,et al.  Automated detection and grading of non-muscle invasive urothelial cell carcinoma of the bladder. , 2020, The American journal of pathology.

[19]  Y. Allory,et al.  Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype , 2020, Cancers.

[20]  Brett Hemamali David J. Andrew J. Daniel M. Chin-Chen Gl Delahunt Samaratunga Grignon Evans Berney P,et al.  Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists , 2020, Modern Pathology.

[21]  Kimmo Kartasalo,et al.  Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. , 2020, The Lancet. Oncology.

[22]  M. Menon,et al.  Rare Histological Variants of Prostate Adenocarcinoma: A National Cancer Database Analysis. , 2019, The Journal of urology.

[23]  D. Sahoo,et al.  Urothelial Proliferation of Unknown Malignant Potential Involving the Bladder: Histopathologic Features and Risk of Progression in De Novo Cases and Cases With Prior Neoplasia. , 2019, Archives of pathology & laboratory medicine.

[24]  O. Elemento,et al.  Clinical features of neuroendocrine prostate cancer. , 2019, European journal of cancer.

[25]  Bram van Ginneken,et al.  Automated Gleason Grading of Prostate Biopsies using Deep Learning , 2019, ArXiv.

[26]  S. Beriwal,et al.  Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis. , 2019, The Prostate.

[27]  T. Powles,et al.  Molecular and histopathology directed therapy for advanced bladder cancer , 2019, Nature Reviews Urology.

[28]  V. Reuter,et al.  PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology , 2019, The American journal of surgical pathology.

[29]  T. Tsuzuki,et al.  The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance , 2019, The Prostate.

[30]  A. D'Amico,et al.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[31]  J. Epstein,et al.  DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant‐cell features , 2019, Histopathology.

[32]  P. Nelson,et al.  Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. , 2019, JCO precision oncology.

[33]  B. Delahunt,et al.  Intraductal carcinoma of the prostate: a critical re-appraisal , 2019, Virchows Archiv.

[34]  J. McKenney.  Precursor lesions of the urinary bladder , 2019, Histopathology.

[35]  A. Lopez‐Beltran,et al.  Variants and new entities of bladder cancer , 2018, Histopathology.

[36]  Mauro A. A. Castro,et al.  A Consensus Molecular Classification of Muscle-invasive Bladder Cancer , 2019, European urology.

[37]  J. Epstein,et al.  PIN-like (Ductal) Adenocarcinoma of the Prostate , 2018, The American journal of surgical pathology.

[38]  Esther I Verhoef,et al.  Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis , 2018, Modern Pathology.

[39]  T. Graeber,et al.  Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage , 2018, Science.

[40]  J. Hicks,et al.  Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases , 2018, The American journal of surgical pathology.

[41]  K. Higgins,et al.  PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma , 2018, The American journal of surgical pathology.

[42]  T. Powles,et al.  Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma , 2018, Nature Reviews Urology.

[43]  Joshua M. Stuart,et al.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.

[44]  Christopher W. Whelan,et al.  Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing , 2018, Cell.

[45]  M. Babjuk,et al.  Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". , 2018, European urology focus.

[46]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[47]  Takafumi N. Yamaguchi,et al.  Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations , 2018, BMC Cancer.

[48]  A. Ravaud,et al.  Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. , 2018, The Lancet. Oncology.

[49]  B. Delahunt,et al.  Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. , 2018, Pathology.

[50]  A. Gown,et al.  Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression , 2017, Modern Pathology.

[51]  D. Margolis,et al.  Population-based study of the incidence and survival for intraductal carcinoma of the prostate. , 2017, Urologic oncology.

[52]  N. Socci,et al.  Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis , 2017, Clinical Cancer Research.

[53]  T. Powles,et al.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[54]  J. McKenney,et al.  Large nested variant of urothelial carcinoma: a clinicopathological study of 36 cases , 2017, Histopathology.

[55]  R. Shah,et al.  Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma , 2017, Histopathology.

[56]  T. H. van der Kwast,et al.  A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. , 2017, European urology.

[57]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[58]  D. Murphy,et al.  Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. , 2017, European urology.

[59]  K. Hoadley,et al.  Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. , 2017, European urology.

[60]  Nicholas J. Vogelzang,et al.  Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study , 2017, JAMA oncology.

[61]  J. Eshleman,et al.  MSH2 Loss in Primary Prostate Cancer , 2017, Clinical Cancer Research.

[62]  L. Salomon,et al.  Ductal adenocarcinoma of the prostate: Clinical and biological profiles , 2017, The Prostate.

[63]  J. Nesland,et al.  Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population‐Based Study , 2017, The Prostate.

[64]  K. Pienta,et al.  Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  R. Shah,et al.  Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate , 2017, The American journal of surgical pathology.

[66]  E. Plimack,et al.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.

[67]  M. Babjuk,et al.  Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC) , 2017, World Journal of Urology.

[68]  C. Sternberg,et al.  The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. , 2016, European urology focus.

[69]  P. Sharma,et al.  Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial , 2016, The Lancet. Oncology.

[70]  T. Curiel,et al.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Daan Nieboer,et al.  Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists , 2016, Histopathology.

[72]  John T. Wei,et al.  Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. , 2016, The Journal of urology.

[73]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[74]  Esther I Verhoef,et al.  Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy , 2016, Modern Pathology.

[75]  G. Netto.  Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma , 2016, The Lancet.

[76]  Aitao Guo,et al.  The pathology of urinary bladder lesions with an inverted growth pattern. , 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[77]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[78]  J. Epstein,et al.  Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder. , 2016, Human pathology.

[79]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[80]  Toyonori Tsuzuki,et al.  Diagnosis of “Poorly Formed Glands” Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy: An Interobserver Reproducibility Study Among Urologic Pathologists With Recommendations , 2015, The American journal of surgical pathology.

[81]  J. Hicks,et al.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas , 2015, The Prostate.

[82]  J. Epstein,et al.  Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital. , 2015, Urology.

[83]  David C. Smith,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[84]  S. Hazell,et al.  Sarcomatoid carcinoma of the prostate: ERG fluorescence in‐situ hybridization confirms epithelial origin , 2015, Histopathology.

[85]  J. Cheville,et al.  Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer , 2015, Modern Pathology.

[86]  K. McVary,et al.  Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer. , 2015, Anticancer research.

[87]  Ewout W Steyerberg,et al.  Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer , 2015, Modern Pathology.

[88]  J. McKiernan,et al.  Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome , 2015, World Journal of Urology.

[89]  Jiao Zhang,et al.  Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[91]  K. Mai,et al.  Nested and microcystic variants of urothelial carcinoma displaying immunohistochemical features of basal‐like urothelial cells: An immunohistochemical and histopathogenetic study , 2014, Pathology international.

[92]  B. Miles,et al.  Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion. , 2014, Human pathology.

[93]  C. Gulmann,et al.  Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. , 2014, Human pathology.

[94]  G. Hidas,et al.  Mixed high and low grade bladder tumors--are they clinically high or low grade? , 2014, The Journal of urology.

[95]  M. Rubin,et al.  Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.

[96]  R. Montironi,et al.  Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour , 2014, Histopathology.

[97]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[98]  C. Magi-Galluzzi,et al.  Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study , 2013, Histopathology.

[99]  Alan W Partin,et al.  Prognostic Gleason grade grouping: data based on the modified Gleason scoring system , 2013, BJU international.

[100]  David A. Green,et al.  Urothelial carcinoma of the bladder and the upper tract: disparate twins. , 2013, The Journal of urology.

[101]  J. Hicks,et al.  Cytoplasmic PTEN Protein Loss Distinguishes Intraductal Carcinoma of the Prostate from High Grade Prostatic Intraepithelial Neoplasia , 2012, Modern Pathology.

[102]  J. Cheville,et al.  The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. , 2012, The Journal of urology.

[103]  T. H. van der Kwast,et al.  Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. , 2012, European journal of cancer.

[104]  J. Epstein,et al.  Large Nested Variant of Urothelial Carcinoma: 23 Cases Mimicking von Brunn Nests and Inverted Growth Pattern of Noninvasive Papillary Urothelial Carcinoma , 2011, The American journal of surgical pathology.

[105]  Wei Huang,et al.  Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. , 2011, American journal of clinical pathology.

[106]  J. Epstein,et al.  Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. , 2010, Journal of Urology.

[107]  R. Shah,et al.  ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate: Implications for the Distinction Between Intraductal Carcinoma of the Prostate and Cribriform High-grade Prostatic Intraepithelial Neoplasia , 2010, The American journal of surgical pathology.

[108]  P. Tamboli,et al.  Clear cell adenocarcinoma of the urinary bladder: a short review. , 2009, Archives of pathology & laboratory medicine.

[109]  E. Platz,et al.  TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas , 2009, Modern Pathology.

[110]  R. Grobholz,et al.  Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate , 2008, Genes, chromosomes & cancer.

[111]  J. Epstein,et al.  High-grade Prostatic Intraepithelial Neoplasialike Ductal Adenocarcinoma of the Prostate: A Clinicopathologic Study of 28 Cases , 2008, The American journal of surgical pathology.

[112]  P. Unger,et al.  Sarcomatoid carcinoma after radiation treatment of prostatic adenocarcinoma. , 2008, Annals of diagnostic pathology.

[113]  T. Braun,et al.  Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. , 2007, Urology.

[114]  J. Epstein,et al.  Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance , 2006, Modern Pathology.

[115]  J. Epstein,et al.  Sarcomatoid Carcinoma of the Prostate: A Study of 42 Cases , 2006, The American journal of surgical pathology.

[116]  A. Parwani,et al.  Pleomorphic Giant Cell Adenocarcinoma of the Prostate: Report of 6 Cases , 2006, The American journal of surgical pathology.

[117]  P. Humphrey,et al.  Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia , 2006, Modern Pathology.

[118]  K. Fujita,et al.  Primary signet ring cell carcinoma of the prostate: Report and review of 42 cases , 2004, International journal of urology : official journal of the Japanese Urological Association.

[119]  E. Oliva,et al.  Clear Cell Carcinoma of the Urinary Bladder: A Report and Comparison of Four Tumors of Mullerian Origin and Nine of Probable Urothelial Origin With Discussion of Histogenesis and Diagnostic Problems , 2002, The American journal of surgical pathology.

[120]  J. McNeal,et al.  Distinction between intraductal carcinoma of the prostate (IDC‐P), high‐grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression , 2000, The Prostate.

[121]  D. Bostwick,et al.  Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma , 2000, Cancer.

[122]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[123]  M. Becich,et al.  Prostatic carcinoma with signet ring cells: a clinicopathologic and immunohistochemical analysis of 12 cases, with review of the literature. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[124]  J. Epstein,et al.  Papillary urothelial hyperplasia. A precursor to papillary neoplasms. , 1996, The American journal of surgical pathology.